Related studies have shown that signaling pathways such as HER2118, HER3, ALK1, MEK, RAF, CDK, and IDO1 can also be used as targets for HNSCC clinical trials. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.